12°c Partly cloudy
6°c Clear
Health Day - ONLINE EDITION
Drug Approved for Inherited Blood Disorder
Exjade removes excess iron, FDA says
WEDNESDAY, Jan. 23 (HealthDay News) -- Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
Too much iron in the blood can damage vital organs, the agency said Wednesday in a news release.
Thalassemia typically leads to the production of fewer red blood cells and less hemoglobin, a protein that carries oxygen throughout the body. NTDT is a milder form of thalassemia that unlike other forms, does not require frequent blood transfusions. Thalassemia affects about 1,000 people in the United States, the FDA said.
The FDA previously approved Exjade to treat chronic iron overload among people who require blood transfusions.
The drug is produced by Novartis, East Hanover, N.J.
More information
The U.S. National Heart Lung and Blood Institute has more about thalassemia.
More Your Health
- Back to Top
- Return to Your Health
More Your Health
(1 of 15 articles for today)
Illicit drug users in Abbotsford, B.C., sue to back demands for health services
11:29 AM 0ABBOTSFORD, B.C. - Three drug addicts are taking the City of Abbotsford, B.C., to court alleging its public health policies ...
Poll
Ads by Google
You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.
Have Your Say
New to commenting? Check out our Frequently Asked Questions.
The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.